Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children (CAVASTHME)

Toulouse University Hospital

Status

Completed

Conditions

Asthma

Treatments

Procedure: Induced sputum method using hypertonic serum

Study type

Interventional

Funder types

Other

Identifiers

NCT02809560

11 054 03

Details and patient eligibility

About

Asthma affects about 10% of children and 6% of adults in industrialized countries. Lymphocytes (L) Th2, a T cell population (LT) producing interleukin (IL) -4, 5 and 13 are broadly involved in this pathology in experimental models and in humans. Many studies show that the signaling pathways activated by the commitment of T receiver differ depending LT. The identification of specific signaling pathways links to Th2 offer new therapeutic approaches. Precedent study showed that mouse Th2 selectively expressed related to calcium channels sensitive channels Cav1 voltage, normally found in excitable cells where they are defined as receivers dihydropyridine (DHP).

The goal of the present study is to show the presence of Cav1 channels in inflammatory cells in allergic asthmatics and show overexpression of these channels in the peripheral blood mononuclear cells from asthmatic subjects before and / or after stimulation with the TCR in comparison with controls.

Enrollment

60 patients

Sex

All

Ages

6 to 18 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

For Asthmatic children arm :

Girl not in childbearing potential or taking contraceptive treatment
Asthma diagnosis in at least 6 months as defined by clinical symptoms (expiratory dyspnea, wheezing, sibilance) and respiratory function (reversibility of VEMS at least 12% after salbutamol administration)
Allergologic tests positives to airborne allergens : positive prick test and/or specific IgE > 0,35 kU/L for at least one allergen
Asthma severity between mild to moderate based on Global initiative for asthma classification during more than one month with inhaled corticotherapies +/- long term action beta -mimetic long compounds (salmeterol, formoterol)
Patient insured with a social security scheme

For control children arm :

Girl not in childbearing potential or taking contraceptive treatment
No medical history of asthma
No medical history of allergy or symptoms of allergy on skin (atopic dermatitis), respiratory tract (rhino-conjunctivitis, asthma) or food allergy

Exclusion criteria

For both arms:

Chronic respiratory pathology : known occlusive or restrictive respiratory syndrome like interstitial lung disease, neuromuscular disease, mucoviscidoses, respiratory tract abnormalities with cough, dyspnea or digital hippocratism.
History of pulmonary or nose and throat infectious disease during last 4 months
Parasitic disease non treated during last 3 months
Dyspnea during the inclusion
Systemic corticotherapy during the last 3 months before inclusion
Immunosuppressive therapy during the last 3 months before inclusion
Diabeta
Disease causing immune disorder
Infection during inclusion
Participation to another study witch implies medical treatment during last 3 months before inclusion

For asthmatic children arm :

Chronic pulmonary pathology (excluding asthma)
Asthma exacerbation during inclusion
VEMS < 70% of normal range or VEMS < 70% of normal range after inhalation of serum (despite salbutamol administration)
Patient unable to complete pulmonary function testing